Literature DB >> 32817957

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19.

Lauren B Rodda, Jason Netland, Laila Shehata, Kurt B Pruner, Peter M Morawski, Christopher Thouvenel, Kennidy K Takehara, Julie Eggenberger, Emily A Hemann, Hayley R Waterman, Mitchell L Fahning, Yu Chen, Jennifer Rathe, Caleb Stokes, Samuel Wrenn, Brooke Fiala, Lauren P Carter, Jessica A Hamerman, Neil P King, Michael Gale, Daniel J Campbell, David Rawlings, Marion Pepper.   

Abstract

The recently emerged SARS-CoV-2 virus is currently causing a global pandemic and cases continue to rise. The majority of infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that might contribute to herd immunity. Thus, we performed a longitudinal assessment of individuals recovered from mildly symptomatic COVID-19 to determine if they develop and sustain immunological memory against the virus. We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset. Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-γ and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies. These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.

Entities:  

Year:  2020        PMID: 32817957      PMCID: PMC7430599          DOI: 10.1101/2020.08.11.20171843

Source DB:  PubMed          Journal:  medRxiv


  7 in total

1.  Coordinated and sustained immune memory responses after mild COVID-19.

Authors:  Aljawharah Alrubayyi
Journal:  Nat Rev Immunol       Date:  2020-11       Impact factor: 53.106

Review 2.  A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2020-09-19

Review 3.  Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.

Authors:  Alessandro Sette; Shane Crotty
Journal:  Immunol Rev       Date:  2022-06-22       Impact factor: 10.983

4.  Frailty and Age Impact Immune Responses to Moderna COVID-19 mRNA Vaccine.

Authors:  Charles T Semelka; Michael E DeWitt; Maria W Blevins; Beth C Holbrook; John W Sanders; Martha A Alexander-Miller
Journal:  Res Sq       Date:  2022-08-01

5.  High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay.

Authors:  Markus H Kainulainen; Eric Bergeron; Payel Chatterjee; Asheley P Chapman; Joo Lee; Asiya Chida; Xiaoling Tang; Rebekah E Wharton; Kristina B Mercer; Marla Petway; Harley M Jenks; Timothy D Flietstra; Amy J Schuh; Panayampalli S Satheshkumar; Jasmine M Chaitram; S Michele Owen; Laura K McMullan; Mike Flint; M G Finn; Jason M Goldstein; Joel M Montgomery; Christina F Spiropoulou
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.996

Review 6.  Adaptive immune responses to SARS-CoV-2.

Authors:  Donald Forthal
Journal:  Adv Drug Deliv Rev       Date:  2021-02-18       Impact factor: 17.873

Review 7.  Cross-reactive memory T cells and herd immunity to SARS-CoV-2.

Authors:  Marc Lipsitch; Yonatan H Grad; Alessandro Sette; Shane Crotty
Journal:  Nat Rev Immunol       Date:  2020-10-06       Impact factor: 108.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.